期刊
LEUKEMIA & LYMPHOMA
卷 59, 期 9, 页码 2056-2067出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2017.1393668
关键词
Multiple myeloma; chimeric antigen receptors; BCMA; hematopoietic cell transplantation; CAR; immunotherapy; TCR
资金
- NIH/NCATS [UL1TR00457]
- MSKCC
- LRF
- SITC
- MSK Technology Development Grant
- MSK Cancer Center Support Core Grant [P30 CA008748]
While recent progress has been made in the management of multiple myeloma, it remains a highly fatal malignancy especially among patients with relapsed-refractory disease. Immunotherapy with adoptive T cells targeting myeloma-associated antigens are at various stages of development and have brought about a new hope for cure. This is a review on the emerging field of adoptively transferred engineered T cell based approaches, with an in-depth focus on chimeric antigen receptors (CAR) targeting multiple myeloma. The recent results from CAR T cells targeting B cell maturation antigen are encouraging but eventual resistance to the CAR T cell therapies remain problematic. With newer approaches in therapies for multiple myeloma, the role of transplantation is evolved to form a platform for T cell therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据